Well, I'm impressed
Somebody has a working brain. Changed the financing - now no warrants + a fat premium to "market" makes TRYP look super attractive. They have several drugs in phase 2.
The other ones that are US listed with a phase 2 'shrom similar portfolio are selling - even after a shlacking - like Mind Med at US$521mm - CMPS at $600mm - so there's a ton of upside potential here. Doesn't matter what market does, if they get an FDA approved drug, this is a multi hundred million Co